DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...

The Global Plexiform Neurofibroma Market centers on the treatment of plexiform neurofibromas, benign nerve sheath tumors linked to Neurofibromatosis Type 1 (NF1). These tumors cause significant ...

Parse Biosciences & Graph Therapeutics partner to build large functional immune perturbation atlas: Seattle Thursday, January 22, 2026, 11:00 Hrs [IST] Parse Biosciences, a global ...

An international research team led by Prof. Dr. Sedat Nizamoğlu from the Department of Electrical and Electronics Engineering ...

Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

Earlier this week, Merck and Moderna, two pharmaceutical companies specializing in vaccines, released statements about their collaborative efforts to devel | Cancer ...

OHSU Faculty Excellence and Innovation Awards support research to advance human health Two scientists at Oregon Health & Science ...

Chroma Bio ("nChroma"), a clinical-stage, genetic medicines company advancing in vivo delivery of innovative cargoes, today announced that the first patient has been dosed in the company's Phase 1/2 ...

Astorg, Charterhouse and Grant Avenue Capital are among the PE firms investing in the dietary supplements sector.

Partnership unites AI and single cell technology to map immune dysfunction and improve drug discovery and development ...

Big in 2026 | School is anything but uncool in Chucklefish's magical new life sim, says producer Rosie Ball ...

Regenxbio Inc. faces pivotal catalysts in 2026, notably RGX-121's FDA decision and RGX-202 Duchenne data, potentially ...